Rockville, WA -- (SBWIRE) -- 09/26/2018 -- A fiducial marker is a device designed to serve as a reference for physical comparison and positional verification of tissues during diagnostic and therapeutic applications such as radiotherapy. Fiducial markers are either implanted, placed on the subject, or are measurable markings in the reticle of an optical instrument.

Fiducial Marker Market: Drivers and Restraints

The increasing application of diagnostic imaging owing to large demand for minimum invasive diagnostics procedures is the critical driver for the global fiducial marker market. The application expanse of fiducial markers such as their deployment in magnetic resonance imaging, computed tomography scanning and radiotherapy propelled by growing menace of cancer is a significant driver of the market.

Request Sample of this Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=1026

The benefits of fiducial markers such as greater resolution and contrast, greater accuracy generated are technical drivers of the market. Fiducial markers are effective in cases such as X-ray imaging of soft mobile tissues acting as reliable surrogates. The advent of techniques such as conformal diagnostic and therapeutic systems such as 3-D conformal radiotherapy (3D-CRT), proton therapy, intensity modulated radiotherapy (IMRT) which demand accurate patient positioning and tumor targeting is the procedural driver of the market. The conformal diagnostic and therapeutic techniques are directly fed by demand for reduction of toxicity by careful dose titration which aids the market expanse. The fiducial markers pinpoint the location with greater accuracy and also allow delivery of maximum radiation dose, while sparing healthy tissue. Other drivers of the market are the growing applications of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT).

The growing cases of prostate cancer represents the largest market opportunity for fiducial markers. According to Surveillance, Epidemiology, and End Results (SEER) Program prostate cancer accounts for 9.5 % of all new cancer cases in the US.

The restraints on the global fiducial marker market are the invasive nature of certain fiducial markers, high cost of gold fiducial markers, misplacement or migration to other body areas and the scarcity of trained work force.

Fiducial Marker Market: Segmentation

To gain a bird's eye view of the fiducial marker market, the report is segmented based on components, route of administration, animal models, clinical indications, study design, and region.

Fiducial Marker Market: Overview

The global market for fiducial marker is consolidated with a few large players dominating the scene. The market trends include a definite shift in favor of developing regions of Asia Pacific, such as India, and China. There is also a strong trend of collaboration between large hospitals and service providers to benefit from infrastructure and skill training. Data sharing between players is another trend so as to reduce cost.

Request for Brochure on this report @ https://www.factmr.com/connectus/sample?flag=B&rep_id=1026

Some of the established players operating in the global fiducial marker are Novartis International AG, CIVCO Medical Solutions, JRT Associates, GATTAquant GmbH, CIVCO Radiotherapy, Prince Izant Company, IZI Medical Products, Eckert & Ziegler BEBIG, Stellar Medical, Naslund Medical AB, Veran Medical Technologies, Medtronic plc, and others.

Fiducial marker Market: Regional Wise Outlook

The global fiducial marker market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is expected to account for the largest share of the global fiducial marker market owing to concentration of key market player, large volume of procedures, and burgeoning cancer population. According to Centers for Disease Control and Prevention, out of every 100 Americans, about 13 will develop prostate cancer during their lifetime. The American Cancer Society's projects approximately 164,690 new prostate cancer cases in the United States for 2018.

The Asia Pacific fiducial marker market excluding Japan is expected to grow at the most significant CAGR owing to shifting prevalence of cancer to the developing regions and growing number of screening. China and India are expected to drive a lion's share of the market growth owing to low labor cost and an expanding pool of skilled healthcare expenditure and infrastructure. Europe fiducial marker market is expected to be led by Germany, France and the UK. The Middle East and Africa Fiducial marker market is expected to be skewed in favor of the Gulf countries of Saudi Arabia, Kuwait, and Qatar.

Fiducial Marker Market: Key Players

Some of the major players operating in the global Fiducial marker market are Novartis International AG, CIVCO Medical Solutions, JRT Associates, GATTAquant GmbH, CIVCO Radiotherapy, Prince Izant Company, IZI Medical Products, Eckert & Ziegler BEBIG, Stellar Medical, Naslund Medical AB, Veran Medical Technologies, Medtronic plc, and others. Collaboration between players and hospitals is the most attractive strategy owing to specialized nature of the market and can yield dividend owing to faster adoption and lower cost.

Read Report @ https://www.factmr.com/report/1026/fiducial-marker-market

The global fiducial marker report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.